Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab, Tuvonralimab, and Lenvatinib as Neoadjuvant Therapy for Hepatocellular Carcinoma
NCT07014150Phase 2Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jun 2025
- Primary completion
- May 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of iparomlimab, tuvonralimab in hepatocellular carcinoma (HCC), sponsored by Peking Union Medical College Hospital. Started Jun 2025; status: recruiting.
02
Drugs
iparomlimabtuvonralimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07014150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07014150.